India’s apex clinical trial regulation body will meet urgently to reconsider Serum Institute of India’s proposal after it revised its plan for starting Oxford vaccine's human trials in India.
While US infectious diseases expert Anthony Fauci said long-term effects of exposure to Covid are yet unknown, others said human challenge trials could quicken vaccine search.
OSD in the health ministry Rajesh Bhushan says India is in talks with various stakeholders on vaccines, but has not yet signed any agreement with a vaccine manufacturer.
Even if an effective Covid vaccine is licensed, the manufacturing of doses for administration to world’s population will need collaboration among manufactures.
US infectious disease expert Anthony Fauci said the trial, to be tested at 89 sites, is designed to show the vaccine is at least 60% effective in preventing Covid.
The Serum Institute of India will start manufacturing the vaccine even before the final nod so it is ready with sizeable volumes once the vaccine gets all permissions.
Freight companies face problems ranging from shrinking capacity on container ships and cargo aircraft to a lack of visibility on when a vaccine will arrive.
Nobody is safe in a market where competition is stunted and choice limited. For the industry, meaningful reform will have to start with the government itself.
Data shows re-alignment in India’s exports, with Tamil Nadu & Telangana posting strong growth in 2024-25 as traditional heavyweights Gujarat & Maharashtra see declines. Gujarat still leads, though.
Of the total package, $649 million will be utilised for additional hardware, software, and support services, and the remaining for Major Defence Equipment (MDE).
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
COMMENTS